{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T19:10:26Z","timestamp":1722885026218},"reference-count":37,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T00:00:00Z","timestamp":1457308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bayer Pharmaceutical Division"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>DISTINCT was an 8\u2010week, double\u2010blind, randomized study to investigate the antihypertensive efficacy and safety of various nifedipine gastrointestinal treatment system (GITS)\/candesartan cilexetil (N\/C) dose combinations, vs respective monotherapies or placebo, in patients with diastolic blood pressure (DBP) \u226595 to &lt;110\u00a0mm Hg. The current prespecified analysis compared BP reduction in participants with mild vs moderate baseline hypertension (ie, systolic [S]BP &lt;160\u00a0mm Hg vs \u2265160\u00a0mm Hg and DBP &lt;100\u00a0mm Hg vs \u2265100\u00a0mm Hg). A total of 1362 patients were analyzed by descriptive statistics. In all patient subgroups investigated, the NC combinations (ie, N: 20, 30, or 60 mg; C: 4, 8, 16, or 32 mg daily) provided greater SBP and DBP lowering and higher rates of BP control (defined as BP &lt;140\/90\u00a0mm Hg) than respective monotherapies or placebo, with greatest absolute BP reductions observed in the moderately elevated SBP or DBP subgroups. A trend to dose\u2010response relationship was observed in each subgroup. In each SBP and DBP subgroup, treatment\u2010related vasodilatory events (flushing, headache, or edema) were less frequent for patients receiving NC combination therapy than N monotherapy. These analyses support the use of calcium antagonist and angiotensin receptor blocker combination therapy in patients with both mild and moderate hypertension, for whom effective BP normalization and good drug tolerance would greatly reduce the risk of cardiovascular events.<\/jats:p>","DOI":"10.1002\/jcph.712","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T16:02:55Z","timestamp":1454342575000},"page":"1120-1129","source":"Crossref","is-referenced-by-count":1,"title":["Nifedipine GITS\/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses"],"prefix":"10.1002","volume":"56","author":[{"given":"Sverre E.","family":"Kjeldsen","sequence":"first","affiliation":[{"name":"Oslo University Hospital Ullevaal University of Oslo  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Cha","sequence":"additional","affiliation":[{"name":"KRK Medical Research Institute  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Villa","sequence":"additional","affiliation":[{"name":"Fondazione S. Maugeri\u2014IRCCS  Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[{"name":"University of Milano\u2010Bicocca IRCCS Istituto Auxologico Italiano  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the DISTINCT Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3109\/08037059509077587"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7404.1427"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199015004-00025"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000035855.44620.DA"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2002.02045.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.09.038"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta7310"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht151"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000065"},{"issue":"7","key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/HJH.0000000000000614","article-title":"Effects of blood pressure\u2010lowering on outcome incidence in hypertension: 5. Head\u2010to\u2010head comparisons of various classes of antihypertensive drugs\u2014overview and meta\u2010analyses","volume":"33","author":"Thomopoulos C","year":"2015","journal-title":"J Hypertens"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000447"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)05381-6"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67185-1"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806182"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2009.77"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)01491-0"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/IBPC.S34803"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00627-4"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.04.002"},{"key":"e_1_2_8_22_1","unstructured":"International Conference on Harmonisation. Efficacy E12A Principles for Clinical Evaluation of New Antihypertensive Drugs. U.S. Food and Drug Administration.http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm065004.htm. Accessed January 21 2016."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.03.018"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2007.06689.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000331"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11911-8"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2006.05113.x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286159002400211"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2008.01.004"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200402000-00021"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328342ef04"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e3181bad74e"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.729505"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S13441"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200208000-00001"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2008.157"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.08.007"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098615589905"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.712","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.712","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.712","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T13:44:18Z","timestamp":1696513458000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,7]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1002\/jcph.712"],"URL":"https:\/\/doi.org\/10.1002\/jcph.712","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"type":"print","value":"0091-2700"},{"type":"electronic","value":"1552-4604"}],"subject":[],"published":{"date-parts":[[2016,3,7]]}}}